Browse By Publication: Annals of Oncology

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: No Grouping | Volume | Authors/Creators
Number of items: 20.

Beadle, Geoffrey, Baade, Peter, & Fritschi, Lin (2009) Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers. Annals of Oncology, 20(1), pp. 103-109.
Number of citations in Scopus 13
Number of citations in Web of Science® 9

Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M., Paz-Ares, L., et al. (2014) 2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease. Annals of Oncology, 25(8), pp. 1475-1484.
Number of citations in Scopus 72
Number of citations in Web of Science® 65

Braybrooke, J. P., O'Byrne, Kenneth J., Saunders, M. P., Propper, D. J., Salisbury, A. J., Boardman, P., et al. (1997) A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. Annals of Oncology, 8(3), pp. 294-296.
Number of citations in Scopus 6
Number of citations in Web of Science® 7

Brodowicz, T., O'Byrne, Kenneth J., & Manegold, C. (2012) Bone matters in lung cancer. Annals of Oncology, 23(9), pp. 2215-2222.
Number of full-text downloads 5
Number of citations in Scopus 19
Number of citations in Web of Science® 16

Davis, I. D., Long, A., Yip, S., Espinoza, D., Thompson, J. F., Kichenadasse, G., et al. (2015) EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. Annals of Oncology, 26(6), pp. 1118-1123.
Number of citations in Scopus 5
Number of citations in Web of Science® 5

Eberhardt, W. E. E., De Ruysscher, D., Weder, W., Le Péchoux, C., De Leyn, P., Hoffmann, H., et al. (2015) 2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer. Annals of Oncology, 26(8), pp. 1573-1588.
Number of citations in Scopus 50
Number of citations in Web of Science® 41

Joel, S., O'Byrne, Kenneth J., Penson, R., Papamichael, D., Higgins, A., Robertshaw, H., et al. (1998) A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. Annals of Oncology, 9(11), pp. 1205-1211.
Number of citations in Scopus 16
Number of citations in Web of Science® 15

Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T., Novello, S., et al. (2014) Second ESMO consensus conference on lung cancer : pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 25(9), pp. 1681-1690.
Number of citations in Scopus 58
Number of citations in Web of Science® 48

O'Brien, M. E. R., Anderson, H., Kaukel, E., O'Byrne, Kenneth J., Pawlicki, M., von Pawel, J., et al. (2004) SRL 172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer : phase III results. Annals of Oncology, 15(6), pp. 906-914.
Number of citations in Scopus 80
Number of citations in Web of Science® 73

O'Byrne, Kenneth J., Philip, P. A., Propper, D. J., Braybrooke, J. P., Saunders, M. P., Bates, N. P., et al. (1999) A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. Annals of Oncology, 10(8), pp. 981-983.
Number of citations in Scopus 5
Number of citations in Web of Science® 5

Paz-Ares, L., Tan, E-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., et al. (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology. (In Press)
Number of full-text downloads 33

Ramalingam, S. S., O'Byrne, K., Boyer, M., Mok, T., Jänne, P. A., Zhang, H., et al. (2016) Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): Pooled subset analyses from two randomized trials. Annals of Oncology, 27(3), pp. 423-429.
Number of full-text downloads 5
Number of citations in Scopus 8
Number of citations in Web of Science® 8

Rosell, R., Robinet, G., Szczesna, A., Ramlau, Rodryg, Constenla, M., Mennecier, B. C., et al. (2008) Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Annals of Oncology, 19(2), pp. 362-369.
Number of citations in Scopus 224
Number of citations in Web of Science® 175

Tse, B. W. C., Collins, A., Oehler, M. K., Zippelius, A., & Heinzelmann-Schwarz, V. A. (2014) Antibody-based immunotherapy for ovarian cancer: where are we at? Annals of Oncology, 25(2), pp. 322-331.
Number of citations in Scopus 15
Number of citations in Web of Science® 7

Vansteenkiste, J., Barlesi, F., Waller, C. F., Bennouna, J., Gridelli, C., Goekkurt, E., et al. (2015) Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: Results of an open-label, randomized, controlled phase II study (CERTO). Annals of Oncology, 26(8), pp. 1734-1740.
Number of full-text downloads 3
Number of citations in Scopus 4
Number of citations in Web of Science® 6

Vansteenkiste, J., Crinò, L., Dooms, C., Douillard, J.Y., Faivre-Finn, C., Lim, E., et al. (2014) 2nd ESMO consensus conference on lung cancer : early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Annals of Oncology, 25(8), pp. 1462-1474.
Number of citations in Scopus 59
Number of citations in Web of Science® 56

Waterhouse, Mary, Risch, Harvey, Bosetti, Cristina, Anderson, Kristin, Petersen, Gloria, Bamlet, William, et al. (2015) Vitamin D and pancreatic cancer: A pooled analysis from the Pancreatic Cancer Case-Control Consortium. Annals of Oncology, 26(8), pp. 1776-1783.
Number of citations in Scopus 8
Number of citations in Web of Science® 5

Yang, J.C.-H., Sequist, L.V., Zhou, C., Schuler, M., Geater, S.L., Mok, T., et al. (2016) Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Annals of Oncology, 27(11), pp. 2103-2110.
Number of citations in Web of Science® 2

This list was generated on Sun May 21 14:34:55 2017 AEST.